Can 18F-FDG PET/CT be used to predict the clinical outcome in acute leukemia patients treated with allogeneic hematopoietic stem cell transplantation?

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024823

Enrollment

Unknown

Registered

2019-07-29

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute leukemia

Interventions

Gold Standard:hematological test

Index test:18F-FDG PET/CT

Eligibility

Sex/Gender

All

Age

7 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1)histologically confirmed; 2) patients underwent 18F-FDG PET/CT before or after allo-HCT.

Exclusion criteria

Exclusion criteria: 1) patients with lymphoma cell leukemia; 2) digital image data unavailable for retrospective analysis; 3) patients who received granulocyte colony-stimulating factor (G-CSF) therapy within 1 month before PET/CT scans; 4) time interval between day 0 of allo-HCT and PET/CT scans > 12 months.

Design outcomes

Primary

Measure	Time frame
lymph nodes;	—

Countries

China

Contacts

Public ContactShengming Deng

The First Affiliated Hospital of Soochow University

dshming@163.com+86 15051510189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026